Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened. Inclusion Criteria: 1. ≥18 years old with no restrictions on sex; 2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma; 3. Eastern cooperative oncology group (ECOG) score ≤2 was required; 4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression; 5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk; 6. No symptoms of hemoptysis; 7. Adequate hepatic and renal functions with a negative urine protein; 8. Expected survival of more than 6 months. Exclusion Criteria: 1. currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ; 2. previous malignancy within five years; 3. thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months; 4. uncontrolled or active pulmonary inflammation; 5. participated in other clinical trials; 6. Pregnant women.